



Please place a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	
				09/589,288	
				Filing Date	
				06/08/2000	
				First Named Inventor	
Yu et al.					
Group Art Unit					
1646					
Examiner Name					
S. Prasad					
Attorney Docket Number					
PF343P3C5					

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
sel ↓	B1	09/912,293		ROSEN ET AL.	NOT PUBLISHED	pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 115536 and 197252
↓	B2	08/971,317	A1	WILEY, S.R.	08/02/01	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
sel	B3	WO	98/18921	A1	Human Genome Sciences	5-07-1998		
↓	B4	WO	00/50597	A2	Human Genome Sciences	8-31-2000		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
sel	B5	CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, <i>Arthritis Rheum.</i> (2001) 44:1313-1319.	
↓	B6	MARRIETTE et al., A Role for B Lymphocyte Stimulator (TALL-1, BAFF, THANK, zTNF4) in Sjögren's Syndrome. 65 <sup>th</sup> Annual American College of Rheumatology Scientific Meeting. Nov. 2001.	
	B7	VAUX et al., The Buzz about BAFF. <i>J Clin. Invest.</i> (2002) 109:17-18	
	B8	GROOM et al., Association of BAFF/BLyS overexpression and altered B cells differentiation with Sjogren's Syndrome. <i>J Clin. Invest.</i> (2002) 109:59-68	
↓	B9	ARNETT et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. <i>Arthritis Rheum</i> (1988) 31:315-324	

Examiner Signature	Sarada Prasad	Date Considered	8/10/02
--------------------	---------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.